Avatar

About Karen Jones

Dr Karen Jones PhD. Karen is a Senior Research Scientist with over 10 years of experience in the pharmaceutical industry within the early drug discovery setting. Karen’s area of expertise is in the development of Ion Channel and GPCR assays which are used for compound screening in various formats from small scale bespoke experiments up to large scale fully automated screens. Karen is skilled at problem solving and has a proven track record of delivery with difficult targets leading to publications in peer reviewed journals.

N-Ethylmaleimide increases KCC2 cotransporter activity by modulating transporter phosphorylation.

Abstract K+/Cl- cotransporter 2 (KCC2) is selectively expressed in the adult nervous system and allows neurons to maintain low intracellular Cl- levels. Thus, KCC2 activity is an essential prerequisite for fast hyperpolarizing synaptic inhibition mediated by type A γ-aminobutyric acid (GABAA) receptors, which are Cl--permeable, ligand-gated ion channels. Consistent with this, deficits in the activity of KCC2 [...]

By |2018-07-05T13:46:47+01:00December 1st, 2017|Ion Channels, Publications|Comments Off on N-Ethylmaleimide increases KCC2 cotransporter activity by modulating transporter phosphorylation.

The small molecule CLP257 does not modify activity of the K+/Cl- co-transporter KCC2 but does potentiate GABA A receptor activity.

Read more here: RA Cardarelli, K Jones, LI Pisella, HJ Wobst, LJ McWilliams, PM Sharpe, MP Burnham, DJ Baker, I Chudotvorova, J Guyot, L Silayeva, DH Morrow, N Dekker, S Zicha, PA Davies, J Holenz, ME Duggan, J Dunlop, RJ Mather, Q Wang, I Medina, NJ Brandon, TZ Deeb and SJ Moss. The small molecule CLP257 [...]

By |2018-07-11T14:46:53+01:00December 1st, 2017|Ion Channels, Publications|Comments Off on The small molecule CLP257 does not modify activity of the K+/Cl- co-transporter KCC2 but does potentiate GABA A receptor activity.

A Screening Assay Cascade to Identify and Characterize Novel Selective Estrogen Receptor Downregulators (SERD’s).

Abstract Here, we describe an approach to identify novel selective estrogen receptor downregulator (SERD) compounds with improved properties such as oral bioavailability and the potential of increased efficacy compared to currently marketed drug treatments. Previously, methodologies such as Western blotting and transient cell reporter assays have been used to identify and characterize SERD compounds, but [...]

By |2018-07-05T13:35:31+01:00December 1st, 2015|Publications|Comments Off on A Screening Assay Cascade to Identify and Characterize Novel Selective Estrogen Receptor Downregulators (SERD’s).